DDInter1943 DDInter596
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Vitamin E {u} (Compound) resembles {v} (Compound) Phylloquinone
Phylloquinone {u} (Compound) causes {v} (Side Effect) Injection site reaction
Injection site reaction {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Doxorubicin (Compound)
Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Doxorubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Daunorubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Doxorubicin (Compound)
Vitamin E (Compound) resembles Phylloquinone (Compound) and Phylloquinone (Compound) causes Injection site reaction (Side Effect) and Injection site reaction (Side Effect) is caused by Doxorubicin (Compound)
Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)